AVP and myeloid sarcoma: The last study addressing the matter [127] enrolled 30 RRMS patients who were in remission for at least a year (MS controls), 19 RRMS patients who have suffered a relapse within one week in whom the copeptin levels were measured during relapse (MS relapse) and reassessed in a month’s time afterwards (MS remission), and 30 healthy controls.